NCT05982106View on ClinicalTrials.gov

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions
Myelofibrosis
Interventions
DRUG

TQ05105 Tablets

TQ05105 tablet is a novel JAK2 inhibitor.

Trial Locations (1)

130103

Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY